The Emerging Role of Genetic Testing in Colorectal Cancer
Pashtoon M. Kasi, MD, MBBS, MS, discusses how genetic testing is underutilized in colorectal cancer, despite its ability to guide treatment dosing and adjustment based on the mutations or variations within a patient.
Pashtoon M. Kasi, MD, MBBS, MS, assistant professor of oncology and senior associate consultant in the Division of Hematology/Oncology at Mayo Clinic, discusses how genetic testing is underutilized in colorectal cancer (CRC), despite its ability to guide treatment dosing and adjustment based on the mutations or variations within a patient.
In CRC, specific genes are known to metabolize 5-fluorouracil, capecitabine, or irinotecan. Historical analyses have also shown that patients do much worse in regard to toxicities when given chemotherapy if they harbor a gene abberration, but Kasi says the frequency in which this aberration appears is underestimated.
Need for Systemic Therapy Remains in Sarcoma
November 27th 2023In an interview with Targeted Oncology, Lisa B. Ercolano, MD, discussed the evolving treatment landscape for sarcomas and underscored the pivotal role of molecular profiling, while addressing the need for more efficacious systemic therapies.
Read More
Neoadjuvant Pembro Plus Chemo Shows EFS Benefit at 5-Years in TNBC
November 13th 2023In an interview with Targeted Oncology, Peter Schmid, FRCP, MD, PhD, discussed the implication of findings from the KEYNOTE-522 trial of the addition of pembrolizumab to neoadjuvant chemotherapy in patients with high-risk triple-negative breast cancer.
Read More
